What is the recommended adult dosing for octreotide 100 µg?

Octreotide 100 µg Dosing

For short-acting octreotide 100 µg, the standard adult dosing is 100 µg subcutaneously three times daily (every 8 hours), which serves as the recommended starting dose for carcinoid syndrome and the maintenance dose for acromegaly. 1

Standard Dosing by Indication

Carcinoid Syndrome

• Begin with 100 µg subcutaneously three times daily during the initial 2 weeks of therapy. 1
• Titrate upward in increments of 50-100 µg every 8 hours based on symptom control of diarrhea and flushing. 2
• The typical maintenance dosage range is 100-600 µg daily in 2-4 divided doses, with most patients requiring 150-250 µg three times daily. 3, 4
• Maximum therapeutic doses can control symptoms in up to 93% of patients when properly titrated. 2

Acromegaly

• Start with 50 µg subcutaneously three times daily during the initial 2 weeks. 1
• The standard maintenance dose is 100 µg three times daily (300 µg total daily), which effectively suppresses growth hormone and IGF-1 in the majority of patients. 1, 5
• Doses may be increased up to 500 µg three times daily if needed, though higher doses (750 µg daily) provide no additional biochemical or clinical benefit over 300 µg daily. 5

VIPomas (Vasoactive Intestinal Peptide Tumors)

• The recommended starting range is 200-300 µg daily in 2-4 divided doses during the initial 2 weeks. 1
• Even small doses can produce dramatic cessation of watery diarrhea in VIPoma patients. 6

Transition to Long-Acting Formulations

• When transitioning to octreotide LAR (long-acting release), continue short-acting octreotide 100-250 µg three times daily for approximately 2 weeks after the first LAR injection, as therapeutic levels are not achieved for 10-14 days. 3, 7, 8
• The standard starting dose of octreotide LAR is 20-30 mg intramuscularly every 4 weeks. 3, 4
• Occasional rescue subcutaneous injections of 100-250 µg may be required for breakthrough symptoms for 2-3 months until steady-state levels from LAR are achieved. 3, 8

Important Monitoring Considerations

Glucose Metabolism

• Monitor blood glucose closely, especially during dose titration, as octreotide can cause both hypoglycemia and hyperglycemia in approximately 15% of patients. 7, 4
• Anti-diabetic medication doses may require adjustment. 1

Gallbladder Complications

• Monitor periodically for cholelithiasis and biliary sludge, which develop in 10-14% of patients on chronic therapy. 5
• Discontinue if complications of cholelithiasis are suspected. 1

Vitamin Malabsorption

• Consider monitoring fat-soluble vitamin levels (A and D) during chronic therapy, as octreotide causes fat malabsorption. 7, 4

Thyroid and Cardiac Function

• Monitor thyroid function periodically, as hypothyroidism may occur. 1
• Use caution in patients at risk for bradycardia or conduction abnormalities; dosage adjustment of cardiac medications (beta-blockers) may be necessary. 1

Common Pitfalls to Avoid

• Do not use the 100 µg dose as initial therapy for acute variceal hemorrhage—this requires a 50 µg IV bolus followed by 50 µg/hour continuous infusion. 6
• Do not discontinue short-acting octreotide immediately when starting LAR formulations—overlap for 2 weeks is essential. 7, 8
• Do not assume higher doses are always better—in acromegaly, 750 µg daily offers no advantage over 300 µg daily but increases side effects. 5